{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:25:40Z","timestamp":1744752340895},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12185-015-1775-3","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T03:30:00Z","timestamp":1426822200000},"page":"238-243","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenstr\u00f6m\u2019s macroglobulinemia with bortezomib"],"prefix":"10.1007","volume":"102","author":[{"given":"Mayuko","family":"Izumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Tsunemine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiichi","family":"Kodaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminari","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"key":"1775_CR1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstr\u00f6m\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia. Semin Oncol. 2003;30:110\u20135.","journal-title":"Semin Oncol"},{"key":"1775_CR2","first-page":"194","volume-title":"World Health Organization (WHO) classification of tumors","author":"SH Sweldrow","year":"2008","unstructured":"Sweldrow SH, Berger F, Pileri SA, Harris NL, Jaffe ES, Stein H. lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al., editors. World Health Organization (WHO) classification of tumors. Lyon, France, International Agency for Research on Cancer: Pathology and genetics tumors of haematopoietic and lymphoid tissues; 2008. p. 194\u20135."},{"key":"1775_CR3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","volume":"114","author":"SP Treon","year":"2009","unstructured":"Treon SP. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2009;114:2375\u201385.","journal-title":"Blood"},{"key":"1775_CR4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0002-9343(82)90852-X","volume":"72","author":"D Crisp","year":"1982","unstructured":"Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982;72:915\u201322.","journal-title":"Am J Med"},{"key":"1775_CR5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/sonc.2003.50077","volume":"30","author":"MJ Stone","year":"2003","unstructured":"Stone MJ, McElroy YG, Pestronk A, Reynolds JL, Newman JT, Tong AW. Human monoclonal macroglobulins with antibody activity. Semin Oncol. 2003;30:318\u201324.","journal-title":"Semin Oncol"},{"key":"1775_CR6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2009.n.030","volume":"9","author":"S Berentsen","year":"2009","unstructured":"Berentsen S. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:110\u20132.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1775_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1586\/ehm.13.17","volume":"6","author":"L Souchet-Compain","year":"2013","unstructured":"Souchet-Compain L, Nguyen S, Choquet S, Leblond V. Fludarabine in Waldenstr\u00f6m\u2019s macroglobulinemia. Expert Rev Hematol. 2013;6:229\u201337.","journal-title":"Expert Rev Hematol"},{"key":"1775_CR8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.clml.2013.02.009","volume":"13","author":"L Souchet-Compain","year":"2013","unstructured":"Souchet-Compain L, Nguyen S, Choquet S, Leblond V. Primary therapy of Waldenstr\u00f6m macroglobulinemia with nucleoside analogue-based therapy. Clin Lymphoma Myeloma Leuk. 2013;13:227\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1775_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia. J Clin Oncol. 2009;27:120\u20136.","journal-title":"J Clin Oncol"},{"key":"1775_CR10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.22014","volume":"86","author":"MA Gertz","year":"2011","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:411\u20136.","journal-title":"Am J Hematol"},{"key":"1775_CR11","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol"},{"key":"1775_CR12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2009-09-242917","volume":"115","author":"KR Carson","year":"2010","unstructured":"Carson KR, Beckwith LG, Metha J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115:915.","journal-title":"Blood"},{"key":"1775_CR13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macrogloburinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"1775_CR14","first-page":"210","volume-title":"The Haemolytic Anaemias","author":"JV Dacie","year":"1992","unstructured":"Dacie JV. Auto-immune haemolytic anaemia (AIHA): cold antibody syndromes I idiopathic types: clinical presentation and haematological findings. In: Dacie JV, editor. The Haemolytic Anaemias. Churchhill: Livingstone; 1992. p. 210\u201339."},{"key":"1775_CR15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","volume":"99","author":"U Randen","year":"2014","unstructured":"Randen U, Tr\u00f8en G, Tierens A, Steen C, Warsame A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99:497\u2013504.","journal-title":"Haematologica"},{"key":"1775_CR16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B cell lymphomagenesis. Blood. 2014;123:1637\u201346.","journal-title":"Blood"},{"key":"1775_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3816\/CLM.2009.n.019","volume":"9","author":"C Chen","year":"2009","unstructured":"Chen C, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib in relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:74\u20136.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1775_CR18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstr\u00f6m Macroglobulinemia. J Clin Oncol. 2010;28:1422\u20138.","journal-title":"J Clin Oncol"},{"key":"1775_CR19","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","volume":"122","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Garc\u00eda-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BOR): long-term results of a phase 2 study of the European myeloma network (EMN). Blood. 2013;122:3276\u201382.","journal-title":"Blood"},{"key":"1775_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clml.2013.02.014","volume":"13","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13:235\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1775_CR21","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313\u201320.","journal-title":"Blood"},{"key":"1775_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1775_CR23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood-2009-07-235663","volume":"116","author":"J Kikuchi","year":"2010","unstructured":"Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406\u201317.","journal-title":"Blood"},{"key":"1775_CR24","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","volume":"123","author":"J Shi","year":"2014","unstructured":"Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et al. TNT003, an inhibitor of the serine protease C1\u00a0s, prevents complement activation induced by cold agglutinins. Blood. 2014;123:4015\u201322.","journal-title":"Blood"},{"key":"1775_CR25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-012-1158-y","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka H, Hashimoto S, Sugita Y, Sakai S, Takeda Y, Abe D, et al. Occurrence of lymphoplasmacytic lymphoma 6\u00a0years after amelioration of primary cold agglutinin disease by rituximab therapy. Int H Haematol. 2012;96:501\u20135.","journal-title":"Int H Haematol."},{"key":"1775_CR26","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","volume":"74","author":"F Sanger","year":"1977","unstructured":"Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463\u20137.","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1775-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1775-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1775-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:24Z","timestamp":1559437884000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1775-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1775-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}